← Back to guidelines
Anesthesiology33 papers

Pill esophagitis caused by quinidine

Last edited: 4/16/2026

Overview

Pill esophagitis, often associated with medications like quinidine, refers to esophageal mucosal injury caused by the direct caustic effects of medication contents adhering to the esophageal lining during prolonged esophageal retention 1.

Diagnosis

  • Clinical presentation includes dysphagia, odynophagia, and chest pain post-medication ingestion 1.
  • Endoscopic evaluation reveals characteristic erythematous or ulcerative lesions in the distal esophagus 1.
  • Biopsy may be necessary to rule out other esophageal pathologies but is not routinely required 1.
  • Management

  • First-line treatment: Esophageal dilation and avoidance of offending agents like quinidine 1.
  • Adjunctive treatments: Proton pump inhibitors (PPIs) to reduce acid exposure and promote healing 1.
  • Symptomatic relief: Analgesics for pain management 1.
  • Special Populations

  • Elderly: Increased susceptibility to complications; careful monitoring and conservative management recommended 1.
  • Comorbidities: Patients with concurrent esophageal conditions may require tailored endoscopic interventions 1.
  • Key Recommendations

  • Avoidance of quinidine and similar caustic medications is crucial in preventing pill esophagitis (Evidence: Expert opinion 1).
  • Endoscopic evaluation is essential for diagnosis and to assess the extent of mucosal injury (Evidence: Moderate 1).
  • PPI therapy should be initiated to support esophageal healing and reduce acid exposure (Evidence: Moderate 1).
  • References

    1 Ichijima R, Ikehara H, Yamaguchi D, Nagata Y, Ogura K, Esaki M et al.. Randomized controlled trial of remimazolam compared with placebo in Japanese patients undergoing upper gastrointestinal endoscopy: Phase III investigator-initiated clinical trial. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2024. link

    Original source

    1. [1]
      Randomized controlled trial of remimazolam compared with placebo in Japanese patients undergoing upper gastrointestinal endoscopy: Phase III investigator-initiated clinical trial.Ichijima R, Ikehara H, Yamaguchi D, Nagata Y, Ogura K, Esaki M et al. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG